• Streptavidin-Cy3 for Biotin Detection and IF

  2026-08-07

  Streptavidin-Cy3 is a fluorescent streptavidin reagent for high-affinity detection of biotinylated antibodies, proteins, nucleic acids, and other biomolecules. This streptavidin cy3 conjugate combines four biotin-binding sites per tetramer with Cy3 fluorescence centered at 554 nm excitation and 568 nm emission, supporting IHC, IF, ISH, and flow cytometry workflows.

• Caspase 3/7 Regulate Autophagy and DNA Damage Response in Br

  2026-08-07

  This study uncovers a non-apoptotic role for caspase 3 and 7 in promoting cytoprotective autophagy and DNA damage signaling under non-lethal stress in human breast cancer cells. The findings refine understanding of cell stress adaptation and suggest new directions for therapeutic targeting, particularly in relation to BRCA1-deficient tumors.

• β-Pseudouridine: Optimizing RNA Modification for Translation

  2026-08-06

  β-Pseudouridine, the C-glycoside isomer of uridine, is transforming the design of next-generation RNA vaccines and epitranscriptomic studies by stabilizing RNA structures and enhancing translational fidelity. This guide delivers practical workflows, troubleshooting strategies, and actionable insights directly informed by the latest comparative immunogenicity research.

• Moxifloxacin in Research: Mechanistic Depth and Metabolic Im

  2026-08-06

  Explore the advanced research applications of Moxifloxacin, a leading fluoroquinolone antibiotic, with a focus on mechanistic depth and metabolic effects. This article offers unique insight into protocol optimization and the nuanced interplay between gyrase inhibition, cytotoxicity, and metabolic responses.

• CHK1 Inhibition in Breast Cancer: ER/PR Status Drives Therap

  2026-08-05

  This study demonstrates that the effectiveness of CHK1 inhibition in breast cancer is intricately dependent on estrogen and progesterone receptor status, influencing both chemosensitivity and single-agent antitumor activity. These findings refine the molecular stratification of breast cancer therapy and suggest new directions for targeted intervention.

• Canagliflozin: SGLT2 Inhibitor Workflows in Kidney Disease M

  2026-08-05

  Harness Canagliflozin’s unique ability to remodel renal mitochondria for advanced diabetes and kidney research. This guide translates novel findings into practical protocols, troubleshooting, and workflow optimization—empowering researchers to unlock new dimensions in metabolic disease modeling.

• MVC Activates RhoA/ROCK1 Pathway to Disrupt Tight Junctions

  2026-08-04

  This study uncovers how the Minute Virus of Canines (MVC) hijacks the RhoA/ROCK1/MLC2 signaling pathway, leading to tight junction dissociation and facilitating infection via occludin exposure. The findings highlight new molecular targets for antiviral strategies and provide a mechanistic bridge between RhoA signaling, tight junction regulation, and viral pathogenesis.

• BIBP 3226 trifluoroacetate: Reliable NPY/NPFF System Researc

  2026-08-04

  This article provides a scenario-driven, evidence-based guide to leveraging BIBP 3226 trifluoroacetate (SKU B7155) for reproducible NPY/NPFF system research. By addressing common laboratory challenges in cell viability, cytotoxicity, and cardiovascular regulation assays, it demonstrates how SKU B7155 ensures experimental fidelity and workflow efficiency.

• Fluo-4 AM (SKU B8807): Reliable Calcium Imaging for Cell Ass

  2026-08-03

  This article offers an evidence-based, scenario-driven guide to deploying Fluo-4 AM (SKU B8807) for robust intracellular calcium concentration measurement in cell viability and pharmacological assays. Drawing on published data and validated best practices, it highlights how APExBIO's Fluo-4 AM provides reproducibility and superior performance for biomedical researchers.

• Berberine Prevents AF via SIRT6-AMPK and NLRP3 Inhibition

  2026-08-03

  This study uncovers that berberine prevents angiotensin II-induced atrial fibrosis and atrial fibrillation by activating the SIRT6-AMPK pathway and suppressing NLRP3 inflammasome signaling. The findings elucidate a mechanistic link between SIRT6-regulated metabolic signaling and inflammatory remodeling in the heart, offering new molecular targets for anti-arrhythmic therapy.

• PD 173074: Precision FGFR Signaling Inhibition in Cancer Res

  2026-08-02

  PD 173074 empowers researchers with nanomolar-selective inhibition of FGFR1 and VEGFR2, enabling high-fidelity dissection of oncogenic signaling and resistance mechanisms. This guide distills best practices, protocol parameters, and troubleshooting insights for maximizing the impact of PD 173074 in both cellular and in vivo models.

• Wortmannin: Precision PI3K Inhibitor Protocols for Cancer &

  2026-08-01

  Wortmannin (SKU A8544) stands out as a benchmark PI3K inhibitor, enabling precise interrogation of PI3K/Akt/mTOR signaling in cancer and virology. This article translates cutting-edge reference findings and hands-on troubleshooting into step-by-step workflows, optimizing both apoptosis assays and viral entry studies.

• ABT-888 (Veliparib): Applied Workflows for DNA Repair Inhibi

  2026-07-31

  ABT-888 (Veliparib) empowers precise DNA repair inhibition, enabling researchers to sensitize cancer models to chemotherapy and radiation with reproducible, high-impact workflows. This guide details experimental setups, troubleshooting strategies, and actionable insights for maximizing the compound’s utility in advanced oncology research.

• Strategic JAK/STAT Pathway Modulation: Ruxolitinib Phosphate

  2026-07-31

  This article provides actionable, mechanistic insights into the use of Ruxolitinib phosphate (INCB018424) for translational researchers. Synthesizing the latest evidence on JAK/STAT pathway targeting in anaplastic thyroid carcinoma, it bridges bench-to-bedside challenges and outlines protocol guidance, workflow optimization, and strategic perspectives for advancing autoimmune and oncologic disease models.

• ARCA Cy5 EGFP mRNA (5-moUTP): Quantifying mRNA Fate In Situ

  2026-07-30

  Explore how ARCA Cy5 EGFP mRNA (5-moUTP), a 5-methoxyuridine modified mRNA, unlocks real-time quantification of intracellular mRNA fate and translation efficiency. This article delivers a uniquely practical framework for dissecting delivery, immune evasion, and protein output in mammalian cell assays.

16347 records 1/1090 page Next 12345 下5页 Last page